Mark Rolfe

11.1k citations
62 papers · 9.3k · 3 hit papers · h-index 36

Impact in

  • Oncology top 1%
    • Cancer-related Molecular Pathways
    • Peptidase Inhibition and Analysis
    • Ubiquitin and proteasome pathways
    • Protein Degradation and Inhibitors

Papers in

    • Cancer-related Molecular Pathways 10
    • HER2/EGFR in Cancer Research 5
    • Peptidase Inhibition and Analysis 5
    • Ubiquitin and proteasome pathways 29
    • Protein Degradation and Inhibitors 17

Mark Rolfe

57 papers receiving 9.0k citations

Mark Rolfe's Hit Papers

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer 2009 · 1.7k citations
1.7k0+10+20Years since publication50010001.5k

Peers

Mark Rolfe
Comparison fields: 5 of 132
  • Oncology 3.2k
  • Molecular Biology 7.1k
  • Cell Biology 1.6k
  • Hematology 765
  • Cancer Research 751
Replace Lawrence R. Dick with:
Lawrence R. Dick United States
Janet Plescia United States
Alexei F. Kisselev United States
Dwayne G. Stupack United States
Jennie Rebecca Lill United States
Catherine L. Day New Zealand
Allen I. Oliff United States
Nicholas Barrie La Thangue United Kingdom
Jamie I. Fletcher Australia
Robert Hromas United States
Mark Rolfe relative to Lawrence R. Dick United States Lawrence R. Dick's profile →
Citations per field
00.5×1.5×
Lawrence R. Dick · 1×
Citations per year

Countries citing papers authored by Mark Rolfe

Since Specialization
Citations

This map shows the geographic impact of Mark Rolfe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Rolfe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Rolfe more than expected).

Fields of papers citing papers by Mark Rolfe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Rolfe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Rolfe. The network helps show where Mark Rolfe may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark Rolfe, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark Rolfe Line = papers co-authored together Mark Rolfe links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 62 papers — load more, or switch the sort, to bring in the rest.

#Work
1
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Hit paper breakdown →
20091697
2
Role of the Ubiquitin-Proteasome Pathway in Regulating Abundance of the Cyclin-Dependent Kinase Inhibitor p27
Hit paper breakdown →
19951656
3
A 20s complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B
Hit paper breakdown →
1995811
4 2006536
5 2010439
6 2010403
7 2015327
8 2010291
9 2018265
10 2004235
11 2010214
12 2009194
13 2020163
14 2015155
15 2006148
16 2003135
17 199798
18 201794
19 199792
20 200692

About Mark Rolfe

Mark Rolfe is a scholar working on Oncology, Molecular Biology, Hematology, Cell Biology and Cancer Research, having authored 62 papers that have together received 9.3k indexed citations. Recurring topics across this work include Ubiquitin and proteasome pathways (29 papers), Protein Degradation and Inhibitors (17 papers), Cancer-related Molecular Pathways (10 papers), Multiple Myeloma Research and Treatments (7 papers), HER2/EGFR in Cancer Research (5 papers), Endoplasmic Reticulum Stress and Disease (5 papers), Peptidase Inhibition and Analysis (5 papers) and NF-κB Signaling Pathways (4 papers). The work is most often cited by research in Oncology (3.2k citations), Molecular Biology (7.1k citations), Cell Biology (1.6k citations), Hematology (765 citations) and Cancer Research (751 citations). Mark Rolfe has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Peggy Beer‐Romero, Michele Pagano, Anne M. Theodoras, Giulio Francesco Draetta, Sun W. Tam, Giannino Del Sal, P. Renée Yew, Vincent Chau, Grzegorz Nalepa and J. Wade Harper. Their work appears in journals such as Blood, Molecular Cancer Therapeutics, Clinical Cancer Research, American Journal of Clinical Pathology and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact